Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-177 pembrolizumab versus standard chemotherapy in first-line MSI-H/dMMR metastatic colorectal cancer
NL-OMON54608Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Pembrolizumab with Standard of care chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jun 2016; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON54608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54608.